Last reviewed · How we verify

NCT06831773

Clinical Study of Carbon Ion Radiotherapy for High-grade Glioma

Recruiting now NA Last updated 18 February 2025
What this trial tests

NA trial testing Carbon ion combined with photon radiotherapy in Carbon Ion Radiotheray in 23 participants. Currently enrolling.

Timeline
1 February 2025
Primary endpoint
31 December 2027
31 December 2027

Quick facts

Lead sponsorGansu Wuwei Tumor Hospital
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment23
Start date1 February 2025
Primary completion31 December 2027
Estimated completion31 December 2027
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Gansu Wuwei Tumor Hospital

Who can join

Adults 14 to 80, any sex, with Carbon Ion Radiotheray or High-grade Glioma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective is to use the advantages of heavy ion physical dosimetry and biology to improve the tumor control rate and long-term survival rate of high-grade glioma, reduce the occurrence of brain tissue radiation damage caused by increasing prescription dose, and provide new treatment suggestions for glioma radiotherapy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Carbon Ion Radiotheray

Currently open trials in the same condition.

Other Gansu Wuwei Tumor Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06831773.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing